Sequential Lenvatinib — Competitive Intelligence Brief

Sequential Lenvatinib (Sequential Lenvatinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor VEGFR, FGFR Oncology Small molecule

Target snapshot

Sequential Lenvatinib (Sequential Lenvatinib) — Sun Yat-sen University. Sequential lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sequential Lenvatinib TARGET	Sequential Lenvatinib	Sun Yat-sen University	phase 3	Tyrosine kinase inhibitor	VEGFR, FGFR
Anlotinib plus Pemetrexed	Anlotinib plus Pemetrexed	Henan Provincial People's Hospital	marketed	Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite	VEGFR, FGFR, RET, c-Kit (anlotinib); thymidylate synthase, DHFR, GARFT (pemetrexed)
Tislelizumab and nintedanib	Tislelizumab and nintedanib	The Affiliated Hospital of Qingdao University	marketed	PD-1 inhibitor + tyrosine kinase inhibitor combination	PD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib)
Anlotinib hydrochloride capsules	Anlotinib hydrochloride capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, FGFR, PDGFR, c-Kit, RET
Anlotinib hydrochloride capsules, Penpulimab injection	Anlotinib hydrochloride capsules, Penpulimab injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Multi-target tyrosine kinase inhibitor + PD-1 inhibitor combination	VEGFR, FGFR, RET, KIT (anlotinib); PD-1 (penpulimab)
Regorafenib and DIBIRI	Regorafenib and DIBIRI	Sun Yat-sen University	phase 3	Multi-kinase inhibitor (regorafenib) combined with topoisomerase I inhibitor (DIBIRI)	VEGFR, FGFR, KIT, RET, RAF (regorafenib); Topoisomerase I (DIBIRI/irinotecan)
HRS-4642 + AG	HRS-4642 + AG	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Tyrosine kinase inhibitor	VEGFR, FGFR, and related receptor tyrosine kinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

1. Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
2. Centre Leon Berard · 2 drugs in this class
3. AB Science · 2 drugs in this class
4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
5. Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
6. Angion Biomedica Corp · 1 drug in this class
7. Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
8. Chang-Ming Huang, Prof. · 1 drug in this class
9. Deciphera Pharmaceuticals, LLC · 1 drug in this class
10. AstraZeneca · 1 drug in this class